drugset / Trial / NCT03724851
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or gastric/gastroesophageal junction adenocarcinoma
Timeline
- Start
- 2018-12-20
- Primary completion
- 2024-05-07
- Completion
- 2024-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vactosertib | Small molecule | 200 mg | Oral |
| Subject | Vactosertib | Small molecule | 300 mg | Oral |